

August 28, 2020

To BSE Limited, P.J. Towers, Dalal Street, Mumbai – 400 001

Dear Sirs,

<u>Sub: Compliance Certificate pursuant to Regulation 13(3) of SEBI</u> (Listing Obligations and Disclosure Reguirements) Regulations, 2015

Scrip Code: 511585

Pursuant to Regulation 13(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Investor Grievance Redressal Report for the Quarter ended March 31, 2020 is as follows:

INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	Nil
Remaining unresolved at the end of the quarter	Nil

Please take note of the same.

Thanking You,

Yours faithfully,

For Rubra Medicaments Limited

Abha Kapoor

Director (Finance) and CFO

DIN - 02799429